Skip to main content

Table 2 Baseline characteristics of the study population (n = 52)

From: Drug-related problems reported by patients with rheumatic diseases: an observational study

Sex (male), n (%)

27 (52%)

Age (years), median (IQR)

68 (62–74)

Diagnosis, number of patients (%)

 

 Rheumatoid arthritis

34 (65%)

 Psoriatic arthritis

7 (13%)

 Spondyloarthritis

3 (6%)

 Polymyalgia rheumatica

3 (6%)

 Gout

3 (6%)

 Osteoarthritis

2 (4%)

 Osteoporosis

1 (2%)

 Polyarthritis

1 (2%)

 Sjogren’s syndrome

1 (2%)

 Temporal arteritis

1 (2%)

Disease duration (years), median (IQR)

10 (5–20)

Medication categories prescribed by rheumatologist, number of patients (%)

 

 DMARDs

 

  csDMARDs

34 (65%)

  bDMARDs

32 (62%)

 Analgesics

 

  NSAIDs

28 (54%)

  Paracetamol

26 (50%)

  Corticosteroids

16 (31%)

  Opioids

4 (8%)

 Other

 

  Gastric acid-reducing drugs

31 (60%)

  Folic acid

27 (52%)

  Osteoporosis medication

20 (38%)

  Laxatives

7 (13%)

  Artificial tears

7 (13%)

  Antigout preparations

2 (4%)

  Raynaud’s syndrome medication

2 (4%)

  Antiemetics

1 (2%)

  1. bDMARD, biologic disease-modifying anti-rheumatic drug; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; DMARD, disease-modifying anti-rheumatic drug; IQR, interquartile range; NSAID, non-steroidal anti-inflammatory drug